Key facts
- Notable investors include Humboldt Fund, Zentynel Frontier Investments.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Momentum Therapeutics (Biotechnology)
- ·The full record, as it builds
Funding rounds
No funding rounds for Momentum Therapeutics (Biotechnology) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Momentum Therapeutics (Biotechnology)
Developer of biotechnology therapeutics intended to address age-related neurodegenerative conditions by targeting aging-associated biological pathways. The company's platform integrates large-scale proteomics data, computational modeling, mapping of protein changes in brain tissue, and experimental validation in laboratory models to identify drug targets and therapeutic candidates, enabling biotechnology and pharmaceutical researchers to study protein dysfunction and develop treatments for neurodegenerative diseases.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2024
- Employees
- 6
- Website
- momentumtx.bio/
- Ownership
- Privately Held (backing)
Momentum Therapeutics (Biotechnology) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Momentum Therapeutics (Biotechnology) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Momentum Therapeutics (Biotechnology) in its N-PORT filings yet. We sweep new filings monthly.